MaxCyte
Gaithersburg, MD
Platform Provider
Program data pending ClinicalTrials.gov matching
· Last scored 2026-10-29
59.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (20)
○ EMA GMP
○ MHRA GMP
Quick Facts: MaxCyte
- Signal Score
- 59.0/100 (as of 2026-10-29)
- Quality Compliance
- Assessment pending
- Headquarters
- Gaithersburg, MD
- Modalities
- CAR-T, Cell Therapy
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About MaxCyte
CDMO.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesCAR-T, Cell Therapy
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
58.0
1 manufacturing site: Gaithersburg, MD
Modalities: CAR-T, Cell Therapy
Capacity assessment: 58.0/100
Sites: Gaithersburg, MD
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
Press Signals20 articles (not scored)
1 manufacturing site: Gaithersburg, MD
Modalities: CAR-T, Cell Therapy
Capacity assessment: 58.0/100
Hiring Activity Beta
Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No count for this company yet. The careers board we can read covers more than this business (3 postings on Nov 20, 2026), and we can't yet tell which of those roles belong to it. Why: the careers board is for the company's instrument business, not contract manufacturing. We'd rather show no number than one that isn't really this company's.
Source:
paylocity
· Checked Nov 20, 2026
Company Signals 20 articles
Company announcements, not verified evidence. They do not change any score.
Liontrust Investment Partners LLP Buys MaxCyte Inc (MXCT) -- Sha - GuruFocus
Liontrust Investment Partners LLP Buys MaxCyte Inc (MXCT) -- Sha GuruFocus
MaxCyte (MXCT) Stock: Short-Term Trend (Technical Strength) 2026-04-27 - Community Volume Signals - Newser
MaxCyte (MXCT) Stock: Short-Term Trend (Technical Strength) 2026-04-27 - Market Hype Signals Newser
MaxCyte (MXCT) Stock: Short-Term Trend (Technical Strength) 2026-04-27 - Community Trade Ideas - Newser
MaxCyte (MXCT) Stock: Short-Term Trend (Technical Strength) 2026-04-27 - Community Trade Ideas Newser
MaxCyte (MXCT) Stock: Short-Term Trend (Technical Strength) 2026-04-27 - Delta Trends - Newser
MaxCyte (MXCT) Stock: Short-Term Trend (Technical Strength) 2026-04-27 - Delta Trends Newser
MXCT (MaxCyte Inc.) shares climb more than four percent after Q4 2025 EPS tops consensus analyst expectations. - Cổng thông tin điện tử Tỉnh Sơn La
MXCT (MaxCyte Inc.) shares climb more than four percent after Q4 2025 EPS tops consensus analyst expectations. Cổng thông tin điện tử Tỉnh Sơn La
MXCT (MaxCyte Inc.) shares climb more than four percent after Q4 2025 EPS tops consensus analyst expectations. - UBND thành phố Hải Phòng
MXCT (MaxCyte Inc.) shares climb more than four percent after Q4 2025 EPS tops consensus analyst expectations. UBND thành phố Hải Phòng
MXCT (MaxCyte Inc.) shares climb more than four percent after Q4 2025 EPS tops consensus analyst expectations. - Xã Vĩnh Công
MXCT (MaxCyte Inc.) shares climb more than four percent after Q4 2025 EPS tops consensus analyst expectations. Xã Vĩnh Công
MXCT (MaxCyte Inc.) shares climb more than four percent after Q4 2025 EPS tops consensus analyst expectations. - Xã Thanh Hà
MXCT (MaxCyte Inc.) shares climb more than four percent after Q4 2025 EPS tops consensus analyst expectations. Xã Thanh Hà
MXCT (MaxCyte Inc.) shares fall 4.09 percent despite Q4 2025 EPS beat and double-digit year over year revenue decline. - Dividend Safety - Newser
MXCT (MaxCyte Inc.) shares fall 4.09 percent despite Q4 2025 EPS beat and double-digit year over year revenue decline. - Expert Verified Trades Newser
Is MaxCyte (MXCT) Stock Good for Passive Investors | Price at $0.74, Down 1.31% - Early Entry - UBND thành phố Hải Phòng
Is MaxCyte (MXCT) Stock Good for Passive Investors | Price at $0.74, Down 1.31% - Early Entry UBND thành phố Hải Phòng
MaxCyte's $136M Fortress Balance Sheet Masks a $4M Structural Headwind as ExPERT DTx Pivot Tests 2026 Inflection - Bitget
MaxCyte's $136M Fortress Balance Sheet Masks a $4M Structural Headwind as ExPERT DTx Pivot Tests 2026 Inflection Bitget
MaxCyte ExPERT Platform: Leading Non-Viral Cell Engineering Technology for Next-Generation Cell & Gene Therapy Development - Minichart
MaxCyte ExPERT Platform: Leading Non-Viral Cell Engineering Technology for Next-Generation Cell & Gene Therapy Development Minichart
MaxCyte's $136M Fortress Balance Sheet Masks a $4M Structural Headwind as ExPERT DTx Pivot Tests 2026 Inflection - Bitget
MaxCyte's $136M Fortress Balance Sheet Masks a $4M Structural Headwind as ExPERT DTx Pivot Tests 2026 Inflection Exchange Bitget
MaxCyte Reports 2025 Financial Results, Announces 2026 Revenue Guidance and Expansion in Cell Therapy Platform 1 - Minichart
MaxCyte Reports 2025 Financial Results, Announces 2026 Revenue Guidance and Expansion in Cell Therapy Platform 1 Minichart
MaxCyte (NASDAQ: MXCT) details 2025 losses and $2B SPL upside - Stock Titan
MaxCyte (NASDAQ: MXCT) details 2025 losses and $2B SPL upside Stock Titan
MaxCyte Reports Lower 2025 Revenue, Provides 2026 Outlook - The Globe and Mail
MaxCyte Reports Lower 2025 Revenue, Provides 2026 Outlook The Globe and Mail
MaxCyte (MXCT) Q4 2025 Earnings Call Transcript - The Globe and Mail
MaxCyte (MXCT) Q4 2025 Earnings Call Transcript The Globe and Mail
MaxCyte (MXCT) Q4 2025 Earnings Call Transcript - AOL.com
MaxCyte (MXCT) Q4 2025 Earnings Call Transcript AOL.com
MaxCyte Q4 Earnings Call Highlights - MarketBeat
MaxCyte Q4 Earnings Call Highlights MarketBeat
Agilent investor relations veteran Parmeet Ahuja joins MaxCyte as CFO - Stock Titan
Agilent investor relations veteran Parmeet Ahuja joins MaxCyte as CFO Stock Titan
Frequently Asked Questions About MaxCyte
What is MaxCyte's CDMO Signal Score?
MaxCyte has a Signal Score of 59/100, based on quality, operations, financial stability, and capacity data.
Evaluating MaxCyte for a manufacturing program?
Use the free AI matchmaker to compare MaxCyte against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 86.3
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
Rose BioSolutions
Rockville, MD · Memphis, TN · Keele, United Kingdom
Signal Score: 64.0
AAV, Lentiviral, Adenoviral, Plasmid, Cell Therapy, CAR-T
Bristol Myers Squibb (CGT Mfg)
Bothell, WA · Warren, NJ
Signal Score: 87.0
CAR-T, Cell Therapy
City of Hope (T Cell Manufacturing)
Duarte, CA
Signal Score: 84.0
CAR-T, Cell Therapy
Minaris Advanced Therapies
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
Signal Score: 83.1
CAR-T, Cell Therapy
Compare MaxCyte with another CDMO
Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.